Immuron LimitedASX: IMCClinical progress supports the longer-term story, but an overheated rebound threatens near-term stability.Stock Performance Profile: (Source: TradingView) 3-Month Performance Profile of IMC on a DTF compared to S&P/ASX 200 (XJO). Immuron delivered a better FY26, with global sales revenue increasing 6% year-on-year to $7.7 million. Australian sales grew 10% to
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
